Expert Answers to Common Questions for Advancing the Standard of Care for Relapsed/Refractory Follicular Lymphoma - a podcast by ReachMD

CME credits: 0.25

Valid until: 07-12-2021

Claim your CME credit at https://reachmd.com/programs/cme/expert-answers-common-questions-advancing-standard-care-relapsedrefractory-follicular-lymphoma/12012/

The anti-CD20 antibody rituximab has been the backbone of initial treatment of follicular lymphoma (FL) as a single agent or in a variety of combination regimens. Although rituximab produces durable responses, the pathobiology of FL is heterogeneous and relapses are common. Patients who present with earlier relapse are particularly challenging to treat because they often have more aggressive disease and will be exposed to multiple lines of therapy to attain disease control.

Fortunately, the treatment of relapsed/refractory FL in the second line and beyond is undergoing a transformation, with multiple agents with novel mechanisms of action recently approved or in late-stage clinical trials. As evidence-based guidelines evolve with the changing treatment landscape, it is more crucial than ever for clinicians to understand the safety and efficacy of newly approved and emerging novel agents for relapsed/refractory FL, and individualize treatment based on patient- and disease-related factors.

AXIS routinely collects and analyzes data gathered from participants in our live grand rounds activities. These questions provide incredible insight regarding the persistent challenges that clinicians face when trying to optimize treatment planning to verify where clinical practice gaps exist. This activity will provide expert answers to questions asked during ...

Further episodes of ReachMD CME

Further podcasts by ReachMD

Website of ReachMD